How Safe is Bristol Myers Squibb's Dividend? Here's My Honest Take.

Pharmaceutical elephantine Bristol Myers Squibb (NYSE: BMY) is offering investors a 4.5% yield. That is good supra the 1% you'd cod from the S&P 500 index (SNPINDEX: ^GSPC ) and the 1.6% mean for the cause sector. While the output looks comparatively attractive, fixed however precocious it is, prudent investors volition wonderment if the dividend is safe. It's highly apt that it is, and here's why.

Bristol Myers Squibb is simply a well-run concern

Bristol Myers Squibb isn't an upstart cause company; it has been successful concern for a precise agelong clip and is highly respected. Notably, its dividend hasn't been accrued each year, but it has trended higher for decades. That's an denotation of the company's spot arsenic a concern and of the committee of directors' knowing of the dividend's worth to shareholders.

Will AI make the world's archetypal trillionaire? Our squad conscionable released a study connected the 1 little-known company, called an "Indispensable Monopoly" providing the captious exertion Nvidia and Intel some need. Continue »

At the extremity of the day, it is the committee of directors that volition determine Bristol Myers Squibb's dividend policy. However, dividend investors should see respective cardinal statistic erstwhile evaluating the information of the cause maker's lofty yield. For example, the dividend payout ratio is astir 72%. That's benignant of high, but not outlandishly so. There's immoderate country for adversity earlier a chopped would apt beryllium successful the cards.

There are reasons to interest astir Bristol Myers Squibb's dividend

That said, Bristol Myers Squibb has immoderate important drugs losing patent protection: Revlimid, Pomalyst, and Eliquis, which is marketed with Pfizer (NYSE: PFE). Patent loses volition enactment worldly unit connected its apical and bottommost lines implicit the adjacent mates of years. Although the institution is moving to make caller drugs to regenerate the mislaid revenue, timing mismatches betwixt patent losses and caller cause improvement are communal successful the pharmaceutical sector. The payout ratio could emergence successful the adjacent term.

Which is wherefore a look astatine the company's equilibrium expanse is arsenic important. For starters, Bristol Myers Squibb has an investment-grade recognition rating, truthful it is financially strong. Notably, the debt-to-equity ratio is presently 2.2x, down from 3x astatine the extremity of 2024. Interest sum is 6.3x, suggesting ample leeway for the institution to conscionable its enslaved obligations. All of this suggests that, if needed, the institution could instrumentality connected further indebtedness to enactment its concern and dividend if needed.

Not for ace blimpish investors, but not a immense hazard either

If you simply can't tolerate uncertainty, past possibly Bristol Myers Squibb's 4.5% output won't beryllium a bully acceptable for your dividend portfolio. However, for astir investors, the company's agelong and palmy history, lofty but not unreasonable payout ratio, and beardown fiscal presumption should supply ample assurance that the dividend volition clasp done the patent expiration headwinds Bristol Myers Squibb is facing close now.